


Syndrome de Détresse



Respiratoire Aigu

TABLE 1. DEFINITIONS OF THE ACUTE RESPIRATORY DISTRESS SYNDROME.*

REFERENCE	YEAR	DEFINITION OR CRITERIA	ADVANTAGES	DISADVANTAGES
Petry and Abbright ¹	1971	Severe dyspnea, tachypnea Cyanosis refractory to oxygen therapy Decreased pulmonary compliance Diffuse alveolar infiltrates on chest radiography Ankle edema, vascular congestion, hemorrhage, pulmonary edema, and hyaline membranes at autopsy	First description Summarizes clinical features well	Lacks specific criteria to identify patients or etiology
Murray et al. ²	1988	Preceding direct or indirect lung injury Mild to moderate or severe lung injury Nonpulmonary organ dysfunction	Includes 4-point lung injury scoring Mild to moderate or severe lung injury Specifies clinical cause of lung injury Includes consideration of the presence or absence of systemic disease	Lung injury score not predictive of outcome Lacks specific criteria to exclude a diagnosis of cardiogenic pulmonary edema
Bernard et al. ³	1994	Acute onset Bilateral infiltrates on chest radiography Pulmonary artery wedge pressure <18 mm Hg or the absence of clinical evidence of left atrial hypertension Acute lung injury considered to be present if PaO_2/FiO_2 is <100 Acute respiratory distress syndrome considered to be present if PaO_2/FiO_2 is <200	Simple, easy to use, especially in clinical trials Recognizes the spectrum of the clinical disorder	Does not specify cause Does not consider the presence or absence of multi-organ dysfunction Radiographic findings not specific

* PaO_2 denotes partial pressure of arterial oxygen, and FiO_2 fraction of inspired oxygen.

Ware & Matthay, 2000

Table 3. Comparison of KCLIP Cohort with Other Population-Based Cohorts in Studies of Acute Lung Injury.^{a,b}

Variable	KCLIP	Scandinavia	Australia
Acute lung injury incidence (cases per 100,000 person-yr)	78.9	17.9	34
Acute lung injury cases (no.)	1113	287	168
Observation period	12 mo, 1999–2000	2 mo, 1997	2 mo, 1999
ICU beds (no.)	450	NA	253
Population denominator (millions)	1.74	11.24	2.9
APACHE II score (mean ±SD)	26.1±8.5	18.7±8	20±9
Mean age (yr)	60.6	59.8	62
Mortality from acute lung injury (%)†	38.5	41.4	32
Mortality from ARDS (%)†	41.1	41.2	34
Ratio of cases of ARDS to cases of acute lung injury (%)	74	77	64
Ratio of cases of acute lung injury to cases of acute respiratory failure (%)	26	23	NA


^a KCLIP denotes King County Lung Injury Project, APACHE II Acute Physiology and Chronic Health Evaluation, ARDS acute respiratory distress syndrome, and NA not available.
^b Mortality figures represent hospital mortality for KCLIP, 90-day mortality for Scandinavia, and 28-day mortality for Australia.

Rubinfeld et al, 2005


TABLE 2. CLINICAL DISORDERS ASSOCIATED WITH THE DEVELOPMENT OF THE ACUTE RESPIRATORY DISTRESS SYNDROME.

DIRECT LUNG INJURY	INDIRECT LUNG INJURY
Common causes	Common causes
Pneumonia	Sepsis
Aspiration of gastric contents	Severe trauma with shock and multiple transfusions
Less common causes	Less common causes
Pulmonary contusion	Cardiopulmonary bypass
Fat emboli	Drug overdose
Near-drowning	Acute pancreatitis
Inhalational injury	after lung transplantation or pulmonary embolectomy





Ware & Matthay, 2000






Ware & Matthay, 2000



Ware & Matthay, 2000

















NIH NHLBI ARDS Network



Prospective, Randomized, Multi-Center Trial of 12 ml/kg Vs 6 ml/kg Tidal Volume Positive Pressure Ventilation for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome

"Respiratory Management in ALI/ARDS"


ARDSnet







Pelosi et al, 2001




Pelosi et al, 2001

TABLE 3. HISTORY OF ALTERNATIVE VENTILATION STRATEGIES FOR ACUTE LUNG INJURY AND THE ACUTE RESPIRATORY DISTRESS SYNDROME.

Ventilation Strategy	Year	Type of Study	No. of Patients	Findings	Source
High levels of positive end-expiratory pressure	1975	Observational	28	High incidence of pneumothorax	Kilger et al. ¹⁰
Extra-pleural membrane resection	1979	Phase 3 multicenter trial	98	No benefit	Zapol et al. ¹¹
High-frequency jet ventilation	1983	Phase 3 multicenter trial	389	No benefit	Carlson et al. ¹²
Prone/decubal positive end-expiratory pressure (5 cm of water)	1994	Phase 3 multicenter trial	92	No benefit in patients at risk for the acute respiratory distress syndrome	Levent et al. ¹³
Prone-controlled inverse-ratio ventilation	1994	Observational	9	Inconclusive, needs further study	Levent et al. ¹³
Extra-pleural resection of carbon deposits	1994	Phase 3 multicenter trial	49	No benefit	Morris et al. ¹⁴
Liquid ventilation	1996	Observational	10	Probably safe, needs further study	Hirakawa et al. ¹⁵
High-frequency oscillatory ventilation	1997	Observational	17	Probably safe, needs further study	Fort et al. ¹⁶
Prone positioning during ventilation	1997	Observational	13	Inconclusive, needs further study	Mans et al. ¹⁷
Prone positioning during ventilation	2000	Observational	39	Inconclusive, needs further study	Nakan et al. ¹⁸
"Open-lung" approach	1998	Phase 3 multicenter trial	83	Decreased 28-day mortality but not in hospital mortality (as compared with conventional ventilation)	Antoni et al. ¹⁹
Low tidal volumes	1998	Phase 3	128	No benefit in patients at risk for the acute respiratory distress syndrome	Sewam et al. ²⁰
Low tidal volumes	1998	Phase 3	114	No benefit	Reckard et al. ²¹
Low tidal volumes	2000	Phase 2	361	Decreased mortality by 22 percent (as compared with traditional tidal volumes)	Acute Respiratory Distress Syndrome Network

Ware & Matthay, 2000




Derdak et al, 2000

TABLE 4. RESULTS OF CLINICAL TRIALS OF PHARMACOLOGIC TREATMENT FOR ACUTE LUNG INJURY AND THE ACUTE RESPIRATORY DISTRESS SYNDROME.


Treatment	Year	Type of Study	No. of Patients	Findings	Source
Glucocorticoids (during the acute phase)	1987	Phase 3	87	No benefit	Bernard et al. ²²
Glucocorticoids (during the acute phase)	1988	Phase 3	59	No benefit	Lacor et al. ²³
Alprostadil	1989	Phase 3	180	No benefit	Bone et al. ²⁴
Etanercept	1999	Phase 2	248	Stopped for lack of efficacy	Abraham et al. ²⁵
Surfactant	1996	Phase 3	725	No benefit; new preparations and methods of delivery were being studied	Antoni et al. ¹⁹
Glucocorticoids during the following convalescent phase	1998	Phase 3	24	Decreased mortality, but study was small	Meduri et al. ²⁶
Inhaled nitric oxide	1998	Phase 2	177	No benefit	DeLinger et al. ²⁷
Inhaled nitric oxide	1999	Phase 3	283	No benefit	Pavoni et al. ²⁸
Retrosomide	2000	Phase 2	234	No benefit	NHL Acute Respiratory Distress Syndrome Network
Procypridine	1998	Phase 3	214	Stopped for lack of efficacy	Bernard et al. unpublished data
Linezolid	1999	Phase 2-3	235	Stopped for lack of efficacy	Unpublished data

*NIH denotes National Institutes of Health.


Ware & Matthay, 2000




Luhr et al, 1999




Luhr et al, 1999




Luhr et al, 1999




Vincent et al, 2002



Angus et al, 2001



Angus et al, 2001




Angus et al. 2001

TABLE 2. SYMPTOMS AT 6 AND 12 mo*

Symptom Groups	Proportion of Patients Expressing Symptom (%)	
	6 mo	12 mo
Probably related to ARDS	47	43
Lower respiratory tract	43	40
Hoarseness/dysphonia	20	5
Possibly related to ARDS	67	78
Depression, anxiety, or insomnia	57	46
Constitutional	44	38
Cognitive	32	21
Upper respiratory tract	28	19
Unlikely to be related to ARDS	80	73
Musculoskeletal	69	71
Neurological	44	32
Gastrointestinal	21	23
Ear and dental	24	16
Dermatological	15	25

* We classified all symptoms as probably, possibly, or unlikely to be related to ARDS using dual independent review with very good inter-rater agreement (kappa statistic: 0.86).

Angus et al. 2001



Tobin. 2001

Et quoi maintenant?

- Comment déterminer un V_T et PEEP idéal?
Courbes P-V automatisées?
- Quelle(s) technique(s) de recrutement doit-on utiliser?
- Ventilation haute fréquence/oscillation?
- Quel est l'impact de la toxicité à l'oxygène dans l'ARDS?